Table 1 Baseline characteristics of the primary and secondary prevention subgroups
Baseline characteristics | Primary preventionN = 34,372 | Secondary preventionN = 65,283 | P value |
|---|---|---|---|
Demographic characteristics | |||
Mean age, mean (SD) | 50.8 (12.7) | 59.0 (11.2) | < 0.001a |
Age group, n (%) | |||
(−, 45] | 11,392 (33.1) | 6792 (10.4) | |
(45, 55] | 9709 (28.2) | 17,158 (26.3) | |
(55, 65] | 9515 (27.7) | 24,279 (37.2) | |
(65, 75] | 2837 (8.3) | 11,455 (17.5) | |
(75, +) | 919 (2.7) | 5599 (8.6) | |
Female, n (%) | 17,195 (50.0) | 30,285 (46.4) | < 0.001b |
CCI, mean (SD) | 0.5 (0.8) | 1.2 (1.2) | < 0.001a |
Comorbidities, n (%) | |||
Hypertension | 12,485 (36.3) | 53,564 (82.0) | < 0.001b |
Dyslipidemia | 5672 (16.5) | 29,654 (45.4) | < 0.001b |
Diabetes mellitus | 6429 (18.7) | 26,688 (40.9) | < 0.001b |
Chronic kidney disease | 1099 (3.2) | 5503 (8.4) | < 0.001b |
Prior medication use, n (%) | |||
Antiplatelets | 3215 (9.4) | 31,171 (47.7) | < 0.001b |
Antihypertensives | 11,125 (32.4) | 51,142 (78.3) | < 0.001b |
Hypoglycemics | 5537 (16.1) | 23,744 (36.4) | < 0.001b |
Lipid-lowing agents (except statins) | 902 (2.6) | 5087 (7.8) | < 0.001b |
Index statin type, n (%) | |||
Atorvastatin | 15,197 (44.2) | 29,710 (45.5) | < 0.001b |
Fluvastatin | 2954 (8.6) | 5567 (8.5) | 0.720b |
Rosuvastatin | 4277 (12.4) | 8430 (12.9) | 0.035b |
Simvastatin | 11,099 (32.3) | 20,327 (31.1) | < 0.001b |
Others | 845 (2.5) | 1249 (2.0) | < 0.001b |
All-cause resource utilization and cost | |||
Total direct medical cost (CNY), mean (SD) | 2894 (6531) | 8689 (13006) | < 0.001a |
Number of outpatient visits, mean (SD) | 11.4 (16.1) | 32.1 (31.4) | < 0.001a |
Any hospitalization, n (%) | 1245 (0.4) | 9047 (13.9) | < 0.001b |